Park Jeong-Yeol, Kim Dae-Yeon, Suh Dae-Shik, Kim Jong-Hyeok, Kim Yong-Man, Kim Young-Tak, Nam Joo-Hyun
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Int J Gynecol Cancer. 2018 Jan;28(1):11-18. doi: 10.1097/IGC.0000000000001136.
The aim of this study was to evaluate the significance of ovarian endometriosis on the prognosis of ovarian clear cell carcinoma (OCCC).
Patients with OCCC were divided into 2 groups according to the presence of ovarian endometriosis: group 1, no coexisting ovarian endometriosis; group 2, clear cell carcinoma arising from ovarian endometriosis or the presence of ovarian endometriosis elsewhere in the ovary. Clinicopathologic characteristics, disease-free survival (DFS), and overall survival (OS) were compared between the 2 groups.
Of 155 patients with OCCC, 77 were categorized into group 1 and 78 into group 2. Group 2 patients were younger than group 1 (median age, 48 vs 51 years; P = 0.005) and had higher incidence of early-stage disease (stage I, 77% vs 58%; P = 0.001) and lower incidence of lymph node metastasis (4% vs 17%; P = 0.008). Group 2 patients were observed to have a significantly higher 5-year DFS (P < 0.001) and OS (P = 0.001) compared with group 1. In stage I disease, group 2 had a significantly higher 5-year DFS (P = 0.004) and OS (P = 0.016) than did group 1. In the multivariate analysis, coexisting endometriosis and advanced International Federation of Obstetrics and Gynecology stage were significant factors for both DFS and OS rates.
Ovarian clear cell carcinoma with endometriosis was found more frequently in younger women and had a higher incidence of early-stage disease and a lower incidence of lymph node metastasis compared with OCCC without endometriosis. Ovarian endometriosis was associated with improved prognostic factors and a better DFS and OS even in stage I disease. Ovarian endometriosis was an independent prognostic factor for OCCC.
本研究旨在评估卵巢子宫内膜异位症对卵巢透明细胞癌(OCCC)预后的意义。
根据是否存在卵巢子宫内膜异位症,将OCCC患者分为两组:第1组,无并存的卵巢子宫内膜异位症;第2组,起源于卵巢子宫内膜异位症的透明细胞癌或卵巢其他部位存在卵巢子宫内膜异位症。比较两组的临床病理特征、无病生存期(DFS)和总生存期(OS)。
155例OCCC患者中,77例归入第1组,78例归入第2组。第2组患者比第1组患者年轻(中位年龄,48岁对51岁;P = 0.005),早期疾病发生率较高(I期,77%对58%;P = 0.001),淋巴结转移发生率较低(4%对17%;P = 0.008)。观察发现,第2组患者的5年DFS(P < 0.001)和OS(P = 0.001)显著高于第1组。在I期疾病中,第2组的5年DFS(P = 0.004)和OS(P = 0.016)显著高于第1组。在多变量分析中,并存的子宫内膜异位症和国际妇产科联合会晚期分期是DFS和OS率的重要因素。
与无子宫内膜异位症的OCCC相比,伴有子宫内膜异位症的卵巢透明细胞癌在年轻女性中更常见,早期疾病发生率较高,淋巴结转移发生率较低。即使在I期疾病中,卵巢子宫内膜异位症也与较好的预后因素、更好的DFS和OS相关。卵巢子宫内膜异位症是OCCC的独立预后因素。